Muñoz-Lumbreras EG, Valdez CJA, Guzmán AOD, Arias PJJG, Peña MIA

Language: Spanish
References: 10
Page: 1-8
PDF size: 406.56 Kb.

ABSTRACT

Clinical case presentation: A 71-year-old male patient presented with anemic syndrome and macroscopic hematuria. Utrotomography showed left renal cancer and urothelial tumor of the right upper urinary tract of synchronous appearance; Nephroureterectomy with bladder cuff on the right side and partial left nephrectomy were performed, both laparoscopically at the same surgical time.
Relevance: Renal carcinoma represents 2-3 % of primary urological cancers, while upper tract urothelial carcinoma is a rare uroepithelial tumor whose incidence reaches 5-10 % of all urothelial carcinomas. While it is rare for urologic tumors to occur together, it is even rarer to find renal carcinoma combined with upper tract urothelial carcinoma; It is estimated that it occurs in 1.1 % of cases.
Clinical implications: For the treatment of renal cancer combined with upper tract urothelial cancer, radical nephroureterectomy with contralateral partial nephrectomy remains the best treatment option showing good oncological results.
Conclusions: The incidence of synchronous tumors increases simultaneously with the increase in the incidence of genitourinary tumors. Treatment represents a challenge for the urologist and must be individualized according to the patient’s characteristics.

REFERENCES

1. De Silva WSL, De Almeida SR, KarunarathneGDBJ, Samarathunga A a. S, Gannoruwa KMCS,Jayasundara J a. SB. Two Different Upper TractUrological Malignancies on Either Side. CaseReports in Urology. 2021;2021(1): 9981381.https://doi.org/10.1155/2021/9981381.

2. Wang P, Wang L, Du J, Liang G. Chromophoberenal cell carcinoma with ipsilateral ureteralurothelial carcinoma: A case report. Molecularand Clinical Oncology. 2023;18(4): 30. https://doi.org/10.3892/mco.2023.2626.

3. Wu K, Liu X, Wang Y, Wang X, Li X.Clinicopathological characteristics andoutcomes of synchronous renal cell carcinomaand urothelial carcinoma: A populationbasedanalysis. Frontiers in Public Health.2022;10: 994351. https://doi.org/10.3389/fpubh.2022.994351.

4. Qi N, Chen Y, Gong K, Li H. Concurrent renal cellcarcinoma and urothelial carcinoma: long-termfollow-up study of 27 cases. de 2018;16(1): 16.https://doi.org/10.1186/s12957-018-1321-x.

5. Rouprêt M, Seisen T, Birtle AJ, Capoun O,Compérat EM, Dominguez-Escrig JL, et al.European Association of Urology Guidelines onUpper Urinary Tract Urothelial Carcinoma: 2023Update. European Urology. 2023;84(1): 49–64.https://doi.org/10.1016/j.eururo.2023.03.013.

6. Babarasul MH, Bapir R, Rahman DHK,Fakhralddin SS, Kakamad FH, Tahir SH, etal. Synchronous ipsilateral papillary renal cellcarcinoma and urothelial carcinoma: A casereport. Oncology Letters. 2023;25(6): 221.https://doi.org/10.3892/ol.2023.13807.

7. Banapour P, Asanad K, Chan R, Tran VQ.Recurrent papillary renal cell carcinomawith concomitant ipsilateral upper urinarytract urothelial carcinoma and metachronousurothelial carcinoma of the bladder. UrologyCase Reports. 2018;17: 59–61. https://doi.org/10.1016/j.eucr.2018.01.007.

8. Keng Lim Ng. The Etiology of Renal CellCarcinoma and Upper Tract UrothelialCarcinoma. In: Urologic Cancers. Brisbane (AU):Exon Publications; 2022.

9. Hu M, Pan D, Wei Y, Ye L. Atypical RecurrentRenal Cell Carcinoma of the Ipsilateral UreterShowing Typical Symptoms of Upper UrinaryTract Urothelial Carcinoma: A Case Reportand Literature Review. Archivos Espanoles DeUrologia. 2023;76(3): 238–244. https://doi.org/10.56434/j.arch.esp.urol.20237603.27.

10. Mazzaschi G, Giudice GC, Corianò M,Campobasso D, Perrone F, Maffezzoli M, etal. Upper Tract Urinary Carcinoma: A UniqueImmuno-Molecular Entity and a ClinicalChallenge in the Current Therapeutic Scenario.Technology in Cancer Research & Treatment.2023;22: 15330338231159753. https://doi.org/10.1177/15330338231159753.